Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Breast Cancer Monthly Minutes

Evaluation of real-world reports will help with the early clinical assessment of interstitial lung disease potentially associated with CDK4/6 inhibitors.
An electronic home-based multidimensional cancer survivorship program did not clearly affect outcomes in women with breast cancer, although a positive impact was revealed in interviews.
Pooled analyses of overall survival shows the addition of CDK inhibitors to fulvestrant confers a consistent survival benefit in patients with breast cancer.
As mutation-associated targeted therapies are identified, it is critical to address genetic testing disparities.
CDK4/6 inhibitors have similar efficacy; therefore, clinicians should consider toxicity when selecting an optimal therapeutic approach.
Use of chemotherapy near the end of life in patients with metastatic breast cancer may potentially negatively impact quality of life.
Low-dose tamoxifen could be used for prevention and to increase sensitivity of mammograms in premenopausal women.
Researchers report on early results from an effort to develop a predictive model and targeted strategies for communication and intervention for cancer screening during the COVID-19 pandemic.
Based on current drug pricing strategies in the United States, ribociclib combination therapy is unlikely to be cost-effective for treating postmenopausal patients with HR-positive HER2-negative advanced breast cancer.
Page 1 of 2
Results 1 - 10 of 20